公开(公告)号：US10168318B2

公开(公告)日：2019-01-01

申请号：US15613052

申请日：2017-06-02

Applicant: ACEA Biosciences, Inc.

Inventor： Yama A. Abassi ,  Naichen Yu ,  Josephine Atienza ,  Xiao Xu ,  Xiaobo Wang

IPC: G01N33/50 ,  C12Q1/00 ,  G01N27/02 ,  G01N33/543

Abstract: A method of identifying a potential therapeutic compound that affects a Receptor Tyrosine Kinase (RTK) pathway in cancer cells, which includes: providing a device capable of measuring cell-substrate impedance; culturing cancer cells in serum-free media in at least two wells of the device; adding to a first well a proposed therapeutic compound that affects a RTK pathway and a RTK stimulating factor for the RTK pathway to form a test well, and adding to another well the RTK stimulating factor to form a control well; continuously monitoring cell-substrate impedance of the at least two wells and optionally determining cell indices from the monitored cell-substrate impedance; and determining a difference in impedance or optionally cell index between the test well and control well; and if significantly different, concluding the proposed therapeutic compound is therapeutically active in the RTK pathway within the cancer cells.

公开(公告)号：US10067121B2

公开(公告)日：2018-09-04

申请号：US14541024

申请日：2014-11-13

Applicant: ACEA Biosciences, Inc.

Inventor： Yama A. Abassi ,  Naichen Yu ,  Josephine Atienza ,  Xiao Xu ,  Xiaobo Wang

IPC: G01N33/50 ,  C12Q1/00 ,  G01N27/02 ,  G01N33/543

CPC classification number: G01N33/5041 ,  C12Q1/002 ,  G01N27/021 ,  G01N33/5014 ,  G01N33/5438 ,  G01N2333/4716 ,  G01N2333/705 ,  G01N2333/91205 ,  G01N2500/04 ,  G01N2500/10

Abstract: Use of cell-substrate impedance based methods for screening for agonists of G-Protein Coupled Receptors (GPCRs) or inhibitors of a Receptor Tyrosine Kinases (RTKs), identifying compounds that affect GPCR or RTK pathways, validating molecular targets involved in a GPCR or RTK signaling pathways, monitoring dose-dependent functional activation of GPCR or RTK; determining desensitization of a GPCR and identifying a compound capable of affecting RTK activity in cancer cell proliferation.

公开(公告)号：US20190195861A1

公开(公告)日：2019-06-27

申请号：US16237382

申请日：2018-12-31

Applicant: ACEA Biosciences, Inc.

Inventor： Yama A. Abassi ,  Naichen Yu ,  Josephine Atienza ,  Xiao Xu ,  Xiaobo Wang

IPC: G01N33/50 ,  G01N27/02 ,  G01N33/543 ,  C12Q1/00

CPC classification number: G01N33/5041 ,  C12Q1/002 ,  G01N27/021 ,  G01N33/5014 ,  G01N33/5438 ,  G01N2333/4716 ,  G01N2333/705 ,  G01N2333/91205 ,  G01N2500/04 ,  G01N2500/10

Abstract: A method of identifying a therapeutic compound for treating cancer in a human subject, the method including: providing a device that measures cell-substrate impedance; culturing cancer cells in the at least two wells, wherein the cancer cells are obtained from a human subject and have a receptor tyrosine kinase (RTK) pathway; adding to a first well a proposed therapeutic compound that affects an RTK pathway and an RTK stimulating factor for the RTK pathway to form a test well, and adding to another well the RTK stimulating factor to form a control well; continuously monitoring cell-substrate impedance of the at least two wells; and determining a difference in impedance or optionally in cell index between the test well and control well; and if significantly different, concluding the proposed therapeutic compound is therapeutically active in the RTK pathway within the cancer cells of the human subject.

公开(公告)号：US20170370907A1

公开(公告)日：2017-12-28

申请号：US15613052

申请日：2017-06-02

Applicant: ACEA Biosciences, Inc.

Inventor： Yama A. Abassi ,  Naichen Yu ,  Josephine Atienza ,  Xiao Xu ,  Xiaobo Wang

IPC: G01N33/50 ,  G01N33/543 ,  C12Q1/00 ,  G01N27/02

CPC classification number: G01N33/5041 ,  C12Q1/002 ,  G01N27/021 ,  G01N33/5014 ,  G01N33/5438 ,  G01N2333/4716 ,  G01N2333/705 ,  G01N2333/91205 ,  G01N2500/04 ,  G01N2500/10

Abstract: A method of identifying a potential therapeutic compound that affects a Receptor Tyrosine Kinase (RTK) pathway in cancer cells, which includes: providing a device capable of measuring cell-substrate impedance; culturing cancer cells in serum-free media in at least two wells of the device; adding to a first well a proposed therapeutic compound that affects a RTK pathway and a RTK stimulating factor for the RTK pathway to form a test well, and adding to another well the RTK stimulating factor to form a control well; continuously monitoring cell-substrate impedance of the at least two wells and optionally determining cell indices from the monitored cell-substrate impedance; and determining a difference in impedance or optionally cell index between the test well and control well; and if significantly different, concluding the proposed therapeutic compound is therapeutically active in the RTK pathway within the cancer cells.

公开(公告)号：US20150185206A1

公开(公告)日：2015-07-02

申请号：US14541024

申请日：2014-11-13

Applicant: ACEA Biosciences, Inc.

Inventor： Yama A. Abassi ,  Naichen Yu ,  Josephine Atienza ,  Xiao Xu ,  Xiaobo Wang

IPC: G01N33/50 ,  G01N27/02

CPC classification number: G01N33/5041 ,  C12Q1/002 ,  G01N27/021 ,  G01N33/5014 ,  G01N33/5438 ,  G01N2333/4716 ,  G01N2333/705 ,  G01N2333/91205 ,  G01N2500/04 ,  G01N2500/10

Abstract: Use of cell-substrate impedance based methods for screening for agonists of G-Protein Coupled Receptors (GPCRs) or inhibitors of a Receptor Tyrosine Kinases (RTKs), identifying compounds that affect GPCR or RTK pathways, validating molecular targets involved in a GPCR or RTK signaling pathways, monitoring dose-dependent functional activation of GPCR or RTK; determining desensitization of a GPCR and identifying a compound capable of affecting RTK activity in cancer cell proliferation.

Abstract translation: 使用基于细胞底物阻抗的方法筛选G-蛋白偶联受体（GPCR）的激动剂或受体酪氨酸激酶（RTK）的抑制剂，鉴定影响GPCR或RTK途径的化合物，验证参与GPCR或RTK的分子靶标 信号通路，监测GPCR或RTK的剂量依赖性功能活化; 测定GPCR的脱敏作用并鉴定能够影响癌细胞增殖中的RTK活性的化合物。

公开(公告)号：US10725023B2

公开(公告)日：2020-07-28

申请号：US16237382

申请日：2018-12-31

Applicant: ACEA Biosciences, Inc.

Inventor： Yama A. Abassi ,  Naichen Yu ,  Josephine Atienza ,  Xiao Xu ,  Xiaobo Wang

IPC: G01N33/50 ,  G01N33/543 ,  G01N27/02 ,  C12Q1/00

Abstract: A method of identifying a therapeutic compound for treating cancer in a human subject, the method including: providing a device that measures cell-substrate impedance; culturing cancer cells in the at least two wells, wherein the cancer cells are obtained from a human subject and have a receptor tyrosine kinase (RTK) pathway; adding to a first well a proposed therapeutic compound that affects an RTK pathway and an RTK stimulating factor for the RTK pathway to form a test well, and adding to another well the RTK stimulating factor to form a control well; continuously monitoring cell-substrate impedance of the at least two wells; and determining a difference in impedance or optionally in cell index between the test well and control well; and if significantly different, concluding the proposed therapeutic compound is therapeutically active in the RTK pathway within the cancer cells of the human subject.